,KRAS

Anastasia Goloudina1, Fabien Le Chevalier1, Pierre Authié1

  • 1Pasteur-TheraVectys Joint Laboratory, Institut Pasteur, Virology Department, Université de Paris, 28 Rue du Dr. Roux, 75015, Paris, France.

Scientific reports
|July 2, 2025
PubMed
概括

这项研究开发了新的免疫瘤疗法,使用针对KRAS突变的lentiviral载体,通过促进T细胞反应来控制结直肠和肺癌,显示出控制结直肠和肺癌的希望.

相关概念视频

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K